NCT06228846View on ClinicalTrials.gov

An Phase I Study of YY001 in Patients with Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

16

Participants

Timeline

Start Date

July 14, 2022

Primary Completion Date

April 30, 2024

Study Completion Date

May 30, 2024

Conditions

Advanced Solid Tumor

Interventions

DRUG

YY001

Oral

Trial Locations (1)

Unknown

Shanghai East Hospital, Shanghai

All Listed Sponsors

lead

Shanghai Yuyao Biotech Co., Ltd.

INDUSTRY